Literature DB >> 10904113

Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics.

A Sahu1, J D Lambris.   

Abstract

In addition to its essential role in immune defense, the complement system contributes to tissue damage in many clinical conditions. Thus, there is a pressing need to develop therapeutically effective complement inhibitors to prevent these adverse effects. This concept, though old, received little scientific attention until recently. Data from animal models of diseases that have been produced using complement-deficient, knockout, and transgenic animals, as well as data demonstrating that complement proteins are produced in many important tissue sites (including the brain) have attracted the interest of many basic research scientists and applied scientists from the biotechnology field and larger pharmaceutical firms. This resurgence of interest has generated a wealth of new information in the field of complement inhibition. In this article, we comprehensively review up-to-date information in the field of complement inhibitors.

Mesh:

Substances:

Year:  2000        PMID: 10904113     DOI: 10.1016/s0162-3109(00)80299-4

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  34 in total

Review 1.  Complement-targeted therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

2.  A new generation of potent complement inhibitors of the Compstatin family.

Authors:  Aliana López de Victoria; Ronald D Gorham; Meghan L Bellows-Peterson; Jun Ling; David D Lo; Christodoulos A Floudas; Dimitrios Morikis
Journal:  Chem Biol Drug Des       Date:  2011-04-26       Impact factor: 2.817

3.  Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.

Authors:  Masha Fridkis-Hareli; Michael Storek; Istvan Mazsaroff; Antonio M Risitano; Ante S Lundberg; Christopher J Horvath; V Michael Holers
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

Review 4.  Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-07       Impact factor: 3.722

5.  Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin.

Authors:  Phanourios Tamamis; Panayiota Pierou; Chrystalla Mytidou; Christodoulos A Floudas; Dimitrios Morikis; Georgios Archontis
Journal:  Proteins       Date:  2011-08-30

Review 6.  Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.

Authors:  Kosmas Tsakiridis; Andreas Mpakas; George Kesisis; Stamatis Arikas; Michael Argyriou; Stavros Siminelakis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Theodora Tsiouda; Eirini Sarika; Ioanna Katamoutou; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

Review 7.  New milestones ahead in complement-targeted therapy.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Semin Immunol       Date:  2016-06-16       Impact factor: 11.130

8.  Beneficial effect of Eucommia polysaccharides on systemic lupus erythematosus-like syndrome induced by Campylobacter jejuni in BALB/c mice.

Authors:  Long Jiang; Zheng Wang; Hong-Wei Zhu; Hong-Ye Di; Hong Li; Yun-Yi Zhang; Dao-Feng Chen
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

9.  Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver.

Authors:  L Bergamaschini; G Gobbo; S Gatti; L Caccamo; P Prato; M Maggioni; P Braidotti; R Di Stefano; L R Fassati
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

10.  The structure of OMCI, a novel lipocalin inhibitor of the complement system.

Authors:  Pietro Roversi; Olga Lissina; Steven Johnson; Nurfilza Ahmat; Guido C Paesen; Kerstin Ploss; Wilhelm Boland; Miles A Nunn; Susan M Lea
Journal:  J Mol Biol       Date:  2007-03-30       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.